Summit Trail Advisors LLC Purchases New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Summit Trail Advisors LLC acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 4th quarter, Holdings Channel reports. The firm acquired 4,376 shares of the specialty pharmaceutical company’s stock, valued at approximately $539,000.

Other large investors have also bought and sold shares of the company. Creative Planning lifted its stake in shares of Jazz Pharmaceuticals by 21.7% in the 2nd quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock valued at $408,000 after purchasing an additional 680 shares during the period. Sanctuary Advisors LLC bought a new position in Jazz Pharmaceuticals in the second quarter worth $213,000. GAMMA Investing LLC lifted its position in Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 121 shares during the period. Inspire Investing LLC purchased a new position in Jazz Pharmaceuticals during the third quarter valued at $312,000. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Jazz Pharmaceuticals by 21.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 6,890 shares of the specialty pharmaceutical company’s stock valued at $768,000 after buying an additional 1,233 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on JAZZ. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Needham & Company LLC reiterated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Piper Sandler restated an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.00.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $129.98 on Wednesday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $7.86 billion, a price-to-earnings ratio of 18.31, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56. The business has a 50-day simple moving average of $122.56 and a two-hundred day simple moving average of $116.63. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 5,053 shares of company stock valued at $617,442 over the last three months. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.